0001615999 false 12/31 2022 Q1 0001615999 2022-01-01 2022-03-31 0001615999 2022-05-23 0001615999 2022-03-31 0001615999 2021-12-31 0001615999 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001615999 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001615999 us-gaap:SeriesBPreferredStockMember 2022-03-31 0001615999 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001615999 2021-01-01 2021-03-31 0001615999 NPTX:SeriesAPreferredStocksMember 2020-12-31 0001615999 NPTX:SeriesBPreferredStocksMember 2020-12-31 0001615999 us-gaap:CommonStockMember 2020-12-31 0001615999 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001615999 us-gaap:RetainedEarningsMember 2020-12-31 0001615999 2020-12-31 0001615999 NPTX:SeriesAPreferredStocksMember 2021-12-31 0001615999 NPTX:SeriesBPreferredStocksMember 2021-12-31 0001615999 us-gaap:CommonStockMember 2021-12-31 0001615999 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001615999 us-gaap:RetainedEarningsMember 2021-12-31 0001615999 NPTX:SeriesAPreferredStocksMember 2021-01-01 2021-03-31 0001615999 NPTX:SeriesBPreferredStocksMember 2021-01-01 2021-03-31 0001615999 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001615999 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001615999 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001615999 NPTX:SeriesAPreferredStocksMember 2022-01-01 2022-03-31 0001615999 NPTX:SeriesBPreferredStocksMember 2022-01-01 2022-03-31 0001615999 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001615999 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001615999 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001615999 NPTX:SeriesAPreferredStocksMember 2021-03-31 0001615999 NPTX:SeriesBPreferredStocksMember 2021-03-31 0001615999 us-gaap:CommonStockMember 2021-03-31 0001615999 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001615999 us-gaap:RetainedEarningsMember 2021-03-31 0001615999 2021-03-31 0001615999 NPTX:SeriesAPreferredStocksMember 2022-03-31 0001615999 NPTX:SeriesBPreferredStocksMember 2022-03-31 0001615999 us-gaap:CommonStockMember 2022-03-31 0001615999 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001615999 us-gaap:RetainedEarningsMember 2022-03-31 0001615999 NPTX:Phase2STTRStudyGrantMember 2022-01-01 2022-03-31 0001615999 NPTX:Phase2STTRStudyGrantMember NPTX:YearOneMember 2022-01-01 2022-03-31 0001615999 NPTX:Phase2STTRStudyGrantMember NPTX:YearTwoMember 2022-01-01 2022-03-31 0001615999 NPTX:Phase2STTRStudyGrantMember NPTX:YearThreeMember 2022-01-01 2022-03-31 0001615999 us-gaap:RevenueRightsGrantedMember 2022-01-01 2022-03-31 0001615999 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001615999 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001615999 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001615999 us-gaap:FairValueInputsLevel12And3Member 2022-03-31 0001615999 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001615999 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001615999 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001615999 us-gaap:FairValueInputsLevel12And3Member 2021-12-31 0001615999 srt:ChiefExecutiveOfficerMember 2022-03-31 0001615999 srt:ChiefExecutiveOfficerMember 2021-12-31 0001615999 srt:DirectorMember 2021-12-31 0001615999 NPTX:LoansPayableOneMember 2022-01-01 2022-03-31 0001615999 NPTX:LoansPayableOneMember 2022-03-31 0001615999 NPTX:LoansPayableOneMember 2021-12-31 0001615999 NPTX:LoansPayableTwoMember 2022-01-01 2022-03-31 0001615999 NPTX:LoansPayableTwoMember 2022-03-31 0001615999 NPTX:LoansPayableTwoMember 2021-12-31 0001615999 NPTX:LoansPayableThreeMember 2022-01-01 2022-03-31 0001615999 NPTX:LoansPayableThreeMember 2022-03-31 0001615999 NPTX:LoansPayableThreeMember 2021-12-31 0001615999 NPTX:RelatedPartyPromissoryNoteMember 2022-03-31 0001615999 NPTX:RelatedPartyPromissoryNoteMember 2021-12-31 0001615999 NPTX:ThermoFisherScientificMember 2019-09-01 2019-09-30 0001615999 NPTX:ThermoFisherScientificMember 2022-03-31 0001615999 NPTX:ThermoFisherScientific2Member 2021-03-01 2021-03-31 0001615999 NPTX:ThermoFisherScientific2Member 2022-03-31 0001615999 us-gaap:ConvertibleDebtMember 2015-07-24 0001615999 us-gaap:ConvertibleDebtMember 2019-09-26 0001615999 us-gaap:ConvertibleDebtMember 2022-03-31 0001615999 us-gaap:ConvertibleDebtMember 2021-12-31 0001615999 NPTX:SecuritiesPurchaseAgreementMember 2019-12-01 2019-12-31 0001615999 NPTX:N12NotesMember 2020-06-08 0001615999 NPTX:N12NotesMember 2020-06-01 2020-06-08 0001615999 NPTX:N12ConvertiblePromissoryNoteMember 2020-06-23 0001615999 NPTX:N12ConvertiblePromissoryNoteMember 2020-06-01 2020-06-23 0001615999 NPTX:N12ConvertiblePromissoryNoteMember 2021-01-01 2021-09-30 0001615999 2022-03-15 0001615999 2022-03-21 0001615999 2022-03-02 2022-03-21 0001615999 NPTX:N8NotesMember 2022-03-21 0001615999 us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001615999 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001615999 NPTX:KettnerInvestmentsMember NPTX:SecuritiesPurchaseAgreementMember 2020-01-01 2020-01-31 0001615999 NPTX:SecuritiesPurchaseAgreementMember 2020-01-01 2020-01-31 0001615999 srt:ChiefExecutiveOfficerMember NPTX:SecuritiesPurchaseAgreementMember 2020-02-01 2020-02-29 0001615999 NPTX:SecuritiesPurchaseAgreementMember 2020-02-01 2020-02-29 0001615999 NPTX:ConvertibleNotesPayableRelatedPartyMember 2022-01-01 2022-03-31 0001615999 NPTX:ConvertibleNotesPayableRelatedPartyMember 2021-01-01 2021-03-31 0001615999 NPTX:ConvertibleNotesPayableRelatedPartyMember 2022-03-31 0001615999 NPTX:ConvertibleNotesPayableRelatedPartyMember 2021-12-31 0001615999 NPTX:RestrictedCommonStockMember 2021-12-02 2021-12-15 0001615999 NPTX:RestrictedCommonStockMember 2021-12-15 0001615999 NPTX:ConvertibleNotesMember 2021-12-31 0001615999 us-gaap:WarrantMember 2021-12-31 0001615999 NPTX:ConvertibleNotesMember 2022-01-01 2022-03-31 0001615999 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001615999 NPTX:ConvertibleNotesMember 2022-03-31 0001615999 us-gaap:WarrantMember 2022-03-31 0001615999 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001615999 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001615999 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0001615999 2021-02-10 0001615999 NPTX:LetterAgreementMember 2021-01-01 2021-02-10 0001615999 2022-01-01 2022-03-15 0001615999 srt:MinimumMember us-gaap:StockOptionMember 2022-03-31 0001615999 srt:MinimumMember us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001615999 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001615999 2021-01-01 2021-12-31 0001615999 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001615999 srt:ChiefExecutiveOfficerMember 2021-02-28 2021-03-12 0001615999 srt:ChiefExecutiveOfficerMember 2021-03-12 0001615999 2014-03-28 2014-04-01 0001615999 2014-04-01 0001615999 2018-07-02 0001615999 2018-06-28 2018-07-02 0001615999 us-gaap:SubsequentEventMember 2022-04-01 2022-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ________________

Commission File Number: 000-55657

NEUROPATHIX, INC.

(Exact name of registrant as specified in its charter)

Delaware	46-2645343
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3805 Old Easton Road

Doylestown, PA 18902

(Address of principal executive offices including Zip Code)

(858) 883-2642

(Registrant’s telephone number, including area code)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of May 23, 2022, the registrant had 93,810,559 issued and outstanding shares of common stock, par value $0.0001 per share.

Table of Contents

	Page
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements	3
Unaudited Condensed Consolidated Balance Sheets	3
Unaudited Condensed Consolidated Statements of Operations	4
Unaudited Condensed Consolidated Statements of Stockholders' Deficit	5
Unaudited Condensed Consolidated Statements of Cash Flows	6
Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3. Quantitative and Qualitative Disclosures About Market Risk	32
Item 4. Controls and Procedures	32
PART II - OTHER INFORMATION
Item 1. Legal Proceedings	34
Item 1A. Risk Factors	34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 3. Defaults Upon Senior Securities	34
Item 4. Mine Safety Disclosures	34
Item 5. Other Information	34
Item 6. Exhibits	34
Signatures	35

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)


Neuropathix, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

		March 31, 2022			December 31, 2021
ASSETS
CURRENT ASSETS:
Cash	$	102,194		$	15,677
Prepaid expenses		5,833			122,313
Other receivables		400			400
Total Current Assets		108,427			138,390

NON-CURRENT ASSETS:
Property and equipment, net		63,665			69,192
Operating lease right-of-use assets		198,140			—
Security deposits		17,121			17,121
Total Non-Current Assets		278,926			86,313
TOTAL ASSETS	$	387,353		$	224,703

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	824,777		$	799,903
Unearned revenue		—			112,980
Payroll and related liabilities		521,557			530,189
Loan payable		900,000			900,000
Loan payable - related party		42,092			42,092
Convertible notes payable		305,000			305,000
Convertible notes payable - related party, net of debt discount of $0 and $6,028, respectively		150,000			143,972
Finance lease obligations		12,860			12,860
Due to related party, net		31,973			46,860
Operating lease liabilities		114,816			—
Derivative liabilities		695,281			89,171
Total Current Liabilities		3,598,356			2,983,027

LONG TERM LIABILITIES:
Loan payable - long term		107,910			107,910
Convertible notes payable - long term, net of discount of $50,000 and $0, respectively		376,373			376,373
Convertible notes payable - long term - related party, net of debt discount of $100,000 and $0, respectively		—			—
Finance lease obligation - long term		17,359			20,776
Patent purchase liability - long term		381,865			381,865
Operating lease liabilities - long term		83,324			—
Derivative liabilities - long term		1,073,762			341,507
Total Long Term Liabilities		2,040,593			1,228,431
TOTAL LIABILITIES		5,638,949			4,211,458

Commitments and contingencies (Note 14)		—			—

STOCKHOLDERS' DEFICIT:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized
Series A preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000)		—			—
Series B preferred stock, 75 shares designated, 75 issued and outstanding (Liquidation preference of $75,000)		—			—
Common stock, $0.0001 par value, 200,000,000 authorized, 93,060,559 and 91,060,559 issued and outstanding as of March 31, 2022 and December 31, 2021		9,306			9,106
Additional paid-in capital		12,925,852			12,595,288
Accumulated deficit		(18,186,754	)		(16,591,149	)
TOTAL STOCKHOLDERS' DEFICIT		(5,251,596	)		(3,986,755	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	387,353		$	224,703

The accompanying notes are an integral part of these condensed consolidated financial statements


Neuropathix, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

	Three Months Ended March 31,
	2022			2021
NET REVENUES:
Grant revenue	$	207,980		$	32,000
TOTAL NET REVENUES		207,980			32,000

OPERATING EXPENSES:
Research and development		219,760			128,648
General and administrative		354,580			987,189
TOTAL OPERATING EXPENSES		574,340			1,115,837

LOSS FROM OPERATIONS		(366,360	)		(1,083,837	)

OTHER INCOME (EXPENSE):
Interest income (expense), net		(304,553	)		(134,521	)
Change in fair value of derivative liabilities		(924,692	)		(110,216	)
TOTAL OTHER INCOME (EXPENSE)		(1,229,245	)		(244,737	)

NET LOSS BEFORE INCOME TAX	$	(1,595,605	)	$	(1,328,574	)
Income tax expense		—			—
NET LOSS	$	(1,595,605	)	$	(1,328,574	)

Loss per common share - basic and diluted	$	(0.02	)	$	(0.02	)
Weighted average common shares outstanding - basic and diluted		92,349,448			82,806,466

The accompanying notes are an integral part of these condensed consolidated financial statements


Neuropathix, Inc.
Condensed Consolidated Statements of Stockholders' Deficit
(Unaudited)

	Series A Preferred Stock			Series B Preferred Stock			Common Stock
	Shares		Amount	Shares		Amount	Shares		Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Deficit
Balance at December 31, 2020	75	$	0.00	75	$	0.00	77,670,908	$	7,767	$	9,830,944	$	(13,033,363	)	(3,194,652	)
Stock based compensation	—		—	—		—	—		—		453,950		—		453,950
Issuance of common stock for cash	—		—	—		—	7,268,188		727		813,030		—		813,757
Issuance of common stock for conversion of notes payable and accrued interest	—		—	—		—	988,069		99		89,632		—		89,731
Issuance of common stock for services	—		—	—		—	525,000		52		105,243		—		105,295
Issuance of common stock in lieu of deferred compensation	—		—	—		—	692,308		69		89,931		—		90,000
Issuance of common stock due to settlement of accrued expenses	—		—	—		—	520,000		52		103,948		—		104,000
Issuance of common stock for payment of patent purchase liability	—		—	—		—	313,972		31		59,969		—		60,000
Reduction of derivative liability due to conversions	—		—	—		—	—		—		68,072		—		68,072
Net loss	—		—	—		—	—		—		—		(1,328,574	)	(1,328,574	)
Balance at March 31, 2021	75	$	0.00	75	$	0.00	87,978,445	$	8,797	$	11,614,719	$	(14,361,937	)	(2,738,421	)
Balance at December 31, 2021	75	$	0.00	75	$	0.00	91,060,559	$	9,106	$	12,595,288	$	(16,591,149	)	(3,986,755	)
Stock based compensation	—		—	—		—	—		—		277,154		—		277,154
Issuance of common stock for cash	—		—	—		—	2,000,000		200		53,410		—		53,610
Net loss	—		—	—		—	—		—		—		(1,595,605	)	(1,595,605	)
Balance at March 31, 2022	75	$	—	75	$	—	93,060,559	$	9,306	$	12,925,852	$	(18,186,754	)	(5,251,596	)

The accompanying notes are an integral part of these condensed consolidated financial statements


Neuropathix, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Three Months Ended March 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,595,605	)	$	(1,328,574	)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation		5,527			4,445
Amortization of debt discount		6,028			100,187
Stock based compensation		277,154			453,950
Issuance of common stock for services		—			157,294
amortization of right of use assets		26,760			—
Non-cash interest expense		263,673			—
Change in fair value of derivative liabilities		924,692			110,216
Changes in operating assets and liabilities:
Prepaid expenses		—			123,000
Security deposits		116,480			—
Accounts payable and accrued expenses		24,874			(114,302	)
Payroll and related liabilities		(8,632	)		74,748
Unearned revenue		(112,980	)		—
Operating lease liabilities		(26,760	)
Due to related party, net		(14,887	)		(26,843	)
NET CASH USED IN OPERATING ACTIVITIES		(113,676	)		(445,879	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment		—			(8,100	)
NET CASH USED IN INVESTING ACTIVITIES		—			(8,100	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		53,610			757,320
Principal payments toward finance lease obligations		(3,417	)		(2,025	)
Proceeds from convertible notes payable, related parties		100,000			—
Proceeds from convertible notes payable		50,000			—
NET CASH PROVIDED BY FINANCING ACTIVITIES		200,193			755,295

Net increase in cash		86,517			301,316
Cash, beginning of period		15,677			21,874
Cash, end of period	$	102,194		$	323,190

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	546		$	798
Cash paid for taxes	$	—		$	—

NON-CASH ACTIVITIES:
Recognition of right of use asset	$	224,900		$	—
Debt discount upon the issuance of convertible note payable	$	150,000		$	—
Issuance of common stock for conversion of notes payable and accrued interest	$	—		$	89,731
Issuance of common stock for payment of patent purchase liability	$	—		$	60,000
Issuance of common stock in lieu of deferred compensation	$	—		$	90,000
Receivable upon the issuance of common shares	$	—		$	56,438
Property and equipment financed through capital leases	$	—		$	16,537
Reduction of derivative liability	$	—		$	68,072
Settlement of accrued expenses through issuance of common stock	$	—		$	52,000

The accompanying notes are an integral part of these condensed consolidated financial statements

Neuropathix, Inc.

Notes to Condensed Consolidated Financial Statements

For the Three Months Ended March 31, 2022

Note 1 – Organization and Nature of Operations

Neuropathix, Inc. (the “Company”) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 (the “Share Exchange”) with Kannalife Sciences, Inc. (“Kannalife”), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife was treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the “Company” or “we” or “us” or “our”) are Kannalife, unless otherwise differentiated. The Company is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa.

On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Kannalife, Inc.

On November 4, 2020, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State that changed its name to Neuropathix, Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change from “KLFE” to “NPTX.” The Company’s name change and ticker symbol change was reviewed and processed by FINRA and went effective November 6, 2020.

Note 2 - Summary of Significant Accounting Policies

The significant accounting policies used in the preparation of the condensed consolidated financial statements are as follows:

Basis of Presentation

We have prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of our balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2022. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been omitted in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with our audited financial statements and accompanying notes for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2022.

Significant Risks and Uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.

The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

In December 2019, a novel strain of coronavirus, commonly known as COVID-19, surfaced. The spread of COVID-19 around the world since 2020 has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations. The Company’s operations as of March 31, 2022 have not been significantly affected, but may be affected in the future, by the ongoing outbreak of COVID-19 which was declared a pandemic by the World Health Organization. The ultimate disruption which may be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Company’s financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Company’s labor workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company.

Revenue Recognition

It is the Company’s policy that revenues are recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.

Our revenues consist of state and federal research grants and fees received from research services for third-party product development. These revenues are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured.

On September 28, 2021, the Company received a notice of award for a $2.97 million Phase 2 STTR Study Grant (the “NINDS Study Grant Award”) from National Institutes of Health (“NIH”) – National Institute of Neurological Disorders and Stroke (“NINDS”). The NINDS Study Grant Award is funded through the NIH HEAL Initiative (“Helping End Addiction Long-Term”) for Development of Therapies and Technologies Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. The NINDS Study Grant Award sets forth the funding allocation of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3. The Company is able to draw down on the grant to reimburse approved research and development activities. As of March 31, 2022, the Company recognized $207,980 in grant revenue in connection with this grant.

Use of Estimates

The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, valuation of derivative liabilities and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock.

The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 65,074,895 and 29,446,224 for the three months ended March 31, 2022 and 2021, respectively.

Research and Development

In accordance with FASB ASC 730, Research and Development (“ASC 730”) research and development (“R&D”) costs are expensed when incurred. R&D costs include supplies, clinical trial and related clinical manufacturing costs, contract and other outside service and facilities and overhead costs. Total R&D costs for the three months ended March 31, 2022 and 2021, were $219,760 and $128,648, respectively.

Stock Based Compensation

The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation (“ASC 718”), prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense, which is included in the general and administrative expense in the consolidated financial statements based on the estimated grant date fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

Recently adopted accounting standards

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company (as an EGC) that is taking advantage of the extended transition period offered to private entities would apply this for fiscal years beginning after December 15, 2021. On January 1, 2022, the Company adopted ASU 2016-02 and its related amendments, which changed our accounting for leases. As a result of this change, we recognized right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classified them as operating leases. The right-of-use assets and lease liabilities have been measured by the present value of remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.

Note 3 – Going Concern and Management’s Liquidity Plans

The Company’s condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying condensed consolidated financial statements, the Company has had a loss from operations of $1,595,605 and $1,328,574 for the three months ended March 31, 2022 and 2021, respectively. Additionally, the Company had an accumulated deficit of $18,186,754 at March 31, 2022 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. These factors raise substantial doubt about its ability to continue as a going concern.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management plans to raise additional capital through the sale common stock and/or preferred stock or traditional debt. However, there are no assurances that such additional funding will be achieved or that management’s plans will be successful. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 – Fair Value Measurements

The Company follows FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) to measure and disclosure the fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements and establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:

Level 1 - Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

Level 2 - Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

Level 3 - Pricing inputs that are generally unobservable inputs and not corroborated by market data.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments.

Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated.

The following table presents liabilities that are measured and recognized at fair value as of March 31, 2022 and December 31, 2021, on a recurring basis:


	March 31, 2022
	Level 1		Level 2		Level 3		Total Carrying Value
Derivative liabilities	$	—	$	—	$	1,769,043	$	1,769,043

	December 31, 2021
	Level 1		Level 2		Level 3		Total Carrying Value
Derivative liabilities	$	—	$	—	$	430,678	$	430,678

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at March 31, 2022 and December 31, 2021 consisted of the following:

Accounts payable and accrued expenses
	March 31, 2022		December 31, 2021
Accounts payable and accrued expenses	$	478,762	$	485,628
Accrued interest		346,015		314,275
Totals	$	824,777	$	799,903

NOTE 6 – PAYROLL AND RELATED LIABILITIES

Payroll and related liabilities at March 31, 2022 and December 31, 2021 consisted of the following:


	March 31, 2022		December 31, 2021
Payroll	$	279,963	$	288,780
Payroll taxes		241,594		241,409
Totals	$	521,557	$	530,189

As of March 31, 2022, the Company has accrued payroll and payroll taxes in connection with salaries paid and accrued to four officers of the Company which includes $214,463 accrued for the CEO.

As of December 31, 2021, the Company has accrued payroll and payroll taxes in connection with salaries paid and accrued to four officers of the Company which includes $190,000 accrued for the CEO, and $75,000 accrued for executive management.

NOTE 7 – LOAN PAYABLE

Schedule of Loans Payable
		March 31, 2022		December 31, 2021
Loan payable at 8%, matured December 31, 2021	*	$	850,000	$	850,000
Loan payable at 0%, matured June 11, 2021	*		50,000		50,000
Loan payable at 0.25%, matures July 26, 2023	*		107,910		107,910
Total			1,007,910		1,007,910
Less: short term loans			900,000		900,000
Total long-term loans		$	107,910	$	107,910
* - unsecured note

Total interest expense on notes payable, amounted to $16,830 and $16,767 for the three months ended March 31, 2022 and 2021, respectively. Accrued interest related to these notes was $211,827 and $194,997 as of March 31, 2022 and December 31, 2021, respectively.

NOTE 8 – LOAN PAYABLE – RELATED PARTY

As previously reported, the Company borrowed $42,092 and issued a promissory note with a maturity date of March 31, 2020 which was later extended to March 31, 2022. No demand letter has been received and the Company is in negotiations to extend the maturity date of the note.

The loans represent working capital advances from shareholders, bear interest at 0.5%, and grant a security interest in the Company’s assets as collateral. In March 2018, this note was amended, and the original note holder assigned the note to Kettner Investments, LLC, a significant shareholder. The note is now non-interest bearing. Accrued interest related to this note is $226 as of March 31, 2022 and December 31, 2021, respectively.

NOTE 9 – FINANCE LEASE OBLIGATIONS

In September 2019, the Company entered into a lease agreement with Thermo Fisher Scientific to acquire equipment with 48 monthly payments of $941, payable through September 1, 2023, with an effective interest rate of 12% per annum. The outstanding balance of this finance lease was $17,016, secured by equipment with carrying value of $33,346, as of March 31, 2022.

In March 2021, the Company entered into another lease agreement with Thermo Fisher Scientific to acquire equipment with 36 monthly payments of $699, payable through February 29, 2024, with an effective interest rate of 13% per annum. The outstanding balance of this finance lease was $13,203, secured by equipment with carrying value of $19,399, as of March 31, 2022.

NOTE 10 – CONVERTIBLE NOTES PAYABLE

Prior to the Share Exchange, discussed in Note 1, the Company issued a convertible note to an investor, face value of $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to such conversion. On September 26, 2019, the Company issued 1,500,000 shares of common stock for the conversion of $123,627 convertible notes payable and $26,373 of related accrued interest. The outstanding balance on this convertible note was $376,373 as of March 31, 2022 and December 31, 2021.

In December 2019, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell to the investor a $100,000 convertible note bearing interest at 8% per annum (the “Note”). The Note matured two years from the date of issuance. The Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion. The Company may not prepay this Note within the first six months. The Company is in negotiations to extend the maturity date of the note. If, after the first six months of the Note the Company:

	(a)	elects to repay the Note, it must do so at a premium of one hundred and twenty five percent (125%) of the face amount of the Note, together with all unpaid and accrued interest to the date of repayment.
	(b)	elects to involuntarily exercise conversion of this Note to the Holder, the Company must provide written notice to the Holder along with an executed copy of the Company’s Notice of Conversion, specifying that the Note shall be converted into shares of the Company’s Common Stock based upon at an effective conversion price of 75% of the average closing price of the Company’s common stock on the fifteen days prior to conversion.

The embedded conversion feature of this Note was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreement, the Company also sold warrants to the investors to purchase up to an aggregate of 100,000 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 12) resulting in full discount of the Note at issuance.

On June 8, 2020, the Company entered into a securities purchase agreement, dated as of June 2, 2020 (the “Purchase Agreement”), with an accredited investor pursuant to which the investor purchased a 12% unsecured convertible promissory note (the “12% Note”) from the Company. The 12% Note has a principal amount of $165,000 less a $9,000 original issue discount (“OID”) for a purchase price of $156,000, of which $52,000 was paid on June 8, 2020 less $3,100 in transaction fees. The 12% Note matured 12 months from the effective date of each tranche. This note is in default as of June 8, 2021, which may trigger cross defaults on other notes. The Company is in negotiations to extend the maturity date of the Note. All principal amounts and the interest thereon are convertible into shares of the Company’s common stock at the option of the Investor, after six (6) months from the date of the 12% Note. All closings occurred following the satisfaction of customary closing conditions. The 12% Note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of the lesser of (i) 68% multiplied by the lowest Trading Price (representing a discount rate of 32%) during the previous fifteen (15) trading day period ending on the latest complete trading day prior to the date of the 12% Note or (ii) the Variable Conversion Price. In connection with the Purchase Agreement and the 12% Note, the Company issued a common stock purchase warrant to purchase 36,666 shares of the Company’s common stock at $0.75 per share (the “Warrant”) which may be exercised by cashless exercise, exercisable for a period of three years. The 12% Note has a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the 12% Note (see Note 13) resulting in full discount of the 12% Note.

On June 23, 2020, the Company entered into a securities purchase agreement, dated as of June 19, 2020, with an accredited investor pursuant to which the investor purchased a 12% convertible promissory note in the principal amount of $150,000, less $20,750 in transaction-related, broker, legal and due diligence expenses. The note matured on June 19, 2021. This note is in default as of June 19, 2021, which may trigger cross defaults on other notes. The Company is in negotiations to extend the maturity date of the Note. Principal payments on the note shall be made in six (6) installments, each in the amount of $25,000, starting on December 19, 2020, and continuing thereafter each thirty (30) days for five (5) months. Notwithstanding the foregoing, the final payment of principal, and accrued and unpaid interest shall be due on the June 19, 2021. The investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the note into shares of the Company’s common stock, at any time upon an event of default, at a conversion price for each share of common stock equal to the lesser of (i) the lowest trading price during the previous five (5) trading day period ending on the latest complete trading day prior to the date of the note, or (ii) the Variable Conversion Price, subject to certain equitable adjustments. Furthermore, in connection with the securities purchase agreement and the note, the Company issued two common stock purchase warrants each to purchase 115,385 shares of the Company’s common stock at $1.30 per share which may be exercised by cashless exercise, exercisable for a period of five years. One of the warrants only became exercisable upon default of the note. During the third quarter of 2021, the anti-dilution clause was triggered and the exercise price was reset to $0.03 resulting in the number of warrants to be increased to 5,000,568. On March 15, 2022, the anti-dilution clause was triggered in one of the Company’s warrants and the exercise price was reset to $0.01 resulting in the number of those warrants to be increased by 9,499,482 to 15,000,050. The note has a variable conversion price and the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the note (see Note 13) resulting in full discount of the note.

On March 21, 2022, the Company issued three convertible notes for cash on identical terms to three investors for an aggregate face value of $150,000, of which $100,000 was with related parties. These convertible notes are unsecured and bear interest at the rate of 3% per annum. These notes mature on March 21, 2032 and are convertible into restricted shares of common stock at a conversion price equal to the lesser of $0.01 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion. The embedded beneficial conversion feature of these notes meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liabilities as of the date of issuance was in excess of the note (see Note 13) resulting in full discount of the note.

Total interest expense on convertible notes payable, was $15,663 and $94,194 for the three months ended March 31, 2022 and 2021, respectively.

Total accrued interest on convertible notes payable, as of March 31, 2022 and December 31, 2021, was $82,689 and $109,102, respectively.

NOTE 11 – CONVERTIBLE NOTES PAYABLE – RELATED PARTY

In January 2020, the Company sold $100,000, convertible note to Kettner Investments, LLC, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 100,000 shares of common stock under the Securities Purchase Agreement. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note.

In February 2020, the Company sold an additional $50,000, to the CEO of MJNA, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of 50,000 shares of common stock under the Securities Purchase Agreement. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note.

On March 21, 2022, the Company issued and aggregate of $100,000 of convertible notes payable to relates parties, see Note 10.

Total interest expense on convertible notes payable – related party, inclusive of amortization of debt discount of $6,028 and $18,493, amounted to $9,028 and $21,493 for the three months ended March 31, 2022 and 2021, respectively.

Total accrued interest on convertible notes payable – related party, as of March 31, 2022 and December 31, 2021, was $26,178 and $23,178, respectively.

NOTE 12 – PATENT PURCHASE LIABILITY

On December 15, 2021, the Company entered into an amendment agreement with AND/Brenneman that modified the schedule of issuance of shares to the following:

All future Issuances of Shares under the IP Purchase and Transfer Agreement shall commence only upon the earlier of (a.) a full sale and acquisition of Neuropathix, Inc. to a third party acquiror and based upon the price per share of said acquisition of Neuropathix, Inc. by a third party, or (b.) the commencement of a human clinical trial of one or more of the AND Assets.

In the event of the commencement of a human clinical trial, an installment process will commence with 1/5th of the transaction or $60,000 will be exchanged for a certain number of shares of restricted common stock of Neuropathix based upon the average five (5) day closing price of Neuropathix, Inc. common stock prior to December 31st of each year subsequent the commencement of human clinical trials. Future installment issuance of shares of restricted common stock of Neuropathix, Inc. shall have a floor price of $0.05 per share and a ceiling price of $0.60 per share. As a result of the amendment, the shares issued to Brenneman were clawed back in 2021 and amounts originally classified as short term, were reclassified as long term.

NOTE 13 – DERIVATIVE LIABILITIES

The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. In addition, the Company issued warrants with variable conversion provisions. The conversion terms of the convertible notes and warrants are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date.

Based on the various convertible notes described in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows for the three months ended March 31, 2022:

Schedule of Derivative Liabilities
	Derivative Liability - Convertible Notes		Derivative Liability - Warrants		Total
Balance as of December 31, 2021	$	89,171	$	341,507	$	430,678
Change in fair value		746,023		178,669		924,692
Change due to exercise / redemptions		—		—		—
Change due to issuances		413,673		—		413,673
Balance as of March 31, 2022	$	1,248,867	$	520,176	$	1,769,043

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Proceedings

From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in “Legal Proceedings” in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition.

Concentrations

All revenue recognized in the three months ended March 31, 2022 and 2021 was grant revenue. While the Company expects to maintain this contract for the entire term, loss of the grant would significantly impact its operations.

NOTE 15 – STOCKHOLDERS’ DEFICIT

Series A Preferred Stock

Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share.

Series B Preferred Stock

Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share.

Common Stock

The Company is authorized to issue 200,000,000 shares of common stock, par value of $0.0001 per share. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.

Equity Purchase Agreement with Cross & Company

On September 18, 2020, the Company entered into an Equity Purchase Agreement with Cross and Company. We have the right to “put,” or sell, up to 8,108,108 shares of our common stock to Cross. Unless terminated earlier, Cross’s purchase commitment will automatically terminate on the earlier of the date on which Cross shall have purchased shares pursuant to the Equity Purchase Agreement for an aggregate purchase price of $6,000,000 or September 18, 2023. The purchase price per share is calculated at a fifteen percent discount of the lowest trading price of the Company’s common stock during the ten days after Cross and Co. receives the shares.

During the period ending March 31, 2021, the Company issued 3,768,188 shares of common stock to Cross and Co for net proceeds of $463,758.

During the period ending March 31, 2022, the Company issued 2,000,000 shares of common stock to Cross and Co. for net proceeds of $53,610.

Stock Options

During the period ending March 31, 2022, the Company granted options to purchase 250,000 shares of common stock at price $0.12 per share to a certain vendor of the Company that are exercisable for ten 10 years from the date of issuance. These options were valued at $12,450 using Black-Scholes Options Pricing Model.

The remaining expense to be recognized for outstanding stock options through March 2024 is $1,017,335.

For the three months ended March 31, 2022 and 2021, the Company recorded $250,139 and $382,473, respectively, as stock based compensation related to the vesting options which is included in the general and administrative expenses in the condensed consolidated statement of operations and $27,015 and $71,477, respectively, as research and development expense.

The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions for the three months ended March 31, 2022:


Market value of common stock on issuance date	$	0.05
Exercise price	$	0.12
Expected volatility		234.81	%
Expected term (in years)		10
Risk-free interest rate		1.78	%
Expected dividend yields		—

On March 12, 2021, the Company executed a second amendment to its 2019 Equity Incentive Plan to (i) replace all references to “Kannalife, Inc.,” the Company’s former name, to “Neuropathix, Inc.,” and (ii) increase the number of shares of Company common stock authorized for issuance thereunder 20,000,000 shares (the “Second Plan Amendment”).

The Second Plan Amendment was approved by the Company’s Board of Directors on March 12, 2021. The Second Plan Amendment remains subject to shareholder approval, which the Company shall undertake to obtain as soon as reasonably practicable, but in no event later than one year from the amendment date. In the event that the Company does not obtain the requisite shareholder approval of the Second Plan Amendment within one year, the Second Plan Amendment shall not be effective. On March 11, 2022, the majority of shareholders of the Common Stock of the Company voted to ratify the 2019 Plan as amended.

As of March 31, 2022, there were 13,000,000 shares of Company common stock issued and outstanding under the 2019 Plan, as amended.

The following is a summary of outstanding and exercisable options:


	Numbers of Options		Weighted Avg Exercise Price		Weighted Avg Remaining Years
Outstanding as of December 31, 2021		15,550,000	$	0.34		8.81
Granted		250,000		0.12		9.79
Exercised		—		—		—
Forfeited		—		—		—
Expired		—		—		—
Outstanding as of March 31, 2022		15,800,000	$	0.33		8.59
Outstanding as of March 31, 2022, vested		10,122,396	$	0.39		8.45

Warrants

On February 10, 2021, the Company entered into a letter agreement with Lyons Capital, pursuant to which the Company agreed to issue and sell 3,500,000 shares of the Company’s common stock, par value $0.0001 per share, and two warrants to purchase an aggregate of 3,500,000 additional shares of Common Stock, the terms of such warrants are further discussed below, for an aggregate purchase price of $1,207,500. The first warrant grants Lyons Capital the right to purchase up to 1,750,000 shares of common stock at an exercise price of $0.22 per share. The second warrant grants Lyons Capital the right to purchase up to an additional 1,750,000 shares of common stock at an exercise price of $0.27 per share. The warrants are exercisable immediately, will expire five years from the date of issuance, and contain customary provisions allowing for adjustment to the exercise price and number of shares of common stock issuable upon exercise in the event of any stock dividend, recapitalization, reorganization, reclassification, or similar transaction. Lyons Capital has the right to exercise the warrants at any time; provided, however, that subject to limited exceptions, Lyons Capital may not exercise any portion of the warrants if Lyons Capital, together with any of its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise.

On March 15, 2022, the anti-dilution clause was triggered in one of the Company’s warrants and the exercise price was reset to $0.01 resulting in the number of those warrants to be increased by 9,499,482 to 15,000,050.

The following is a summary of outstanding and exercisable warrants:


	Number of Shares		Weighted Average Exercise Price
Balance at December 31, 2021		9,287,234	$	0.11
Issued		—		—
Reset		9,499,482		0.01
Expired		—		—
Balance at March 31, 2022		18,786,716	$	0.06

At March 31, 2022, 18,786,716 warrants for common stock were exercisable and the intrinsic value of these warrants was $362,422 and the weighted average remaining contractual life for warrants outstanding was 3.31 years.

NOTE 16 – RELATED PARTY TRANSACTIONS

The Company’s Chief Executive Officer (“CEO”) shares the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or $2,800 per month.

On March 12, 2021, the Company issued its CEO 692,308 shares of common stock at $0.13 a share in lieu of $90,000 of accrued compensation.

See Notes 8, 11, 14 and 15 for additional related party transactions.

NOTE 17 – LEASES

On April 1, 2014, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. The lease has been renewed through May 2023. The monthly rent payment is $5,600 and the security deposit is $15,000. In May 2022, the monthly rent increased to $5,800.

On July 1, 2018, we entered into a one year lease arrangement for additional office space, with the option to renew the lease annually. On July 1, 2021, the lease was renewed for three 3 years and the monthly rent payment is $6,203.

At March 31, 2022, the future undiscounted minimum lease payments under the noncancellable leases are as follows:


For the nine month period ending December 31, 2022	$	94,844
Year ending December 31, 2023		88,309
Year ending December 31, 2024		30,747
Total undiscounted finance lease payments	$	213,898
Less: Imputed interest		15,759
Present value of finance lease liabilities		198,140

The operating lease liabilities of $198,140 as of March 31, 2022, represents the discounted (at a 8% incremental borrowing rate) value of the future lease payments at March 31, 2022.

For the three months ended March 31, 2022 and 2021, occupancy expense attributed to these leases were $31,081 and 46,309, respectively.

NOTE 18 – SUBSEQUENT EVENTS

In April and May 2022, the Company, exercised put options and sold and aggregate of 750,000, of its common stock to one of its investors under terms of the Equity Purchase Agreement for an aggregate value to be determined after the issuance of this report.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and operating results together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). This discussion and analysis and other parts of this Report contain forward-looking statements based upon current beliefs, plans and expectations that involve various risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” or in other parts of this Report and in the “Risk Factors” section of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2022.

Forward-Looking Statements

This Report, the other reports, statements, and information that the Company has previously filed with or furnished to, or that we may subsequently file with or furnish to, the SEC and public announcements that we have previously made or may subsequently make include, may include, or may incorporate by reference certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and that are intended to enjoy the protection of the safe harbor for forward-looking statements provided by that Act. To the extent that any statements made in this Report contain information that is not historical, these statements are forward-looking. Forward-looking statements can be identified by the use of words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, marketability of our products; legal and regulatory risks associated with our business and trading publicly; our ability to raise additional capital to finance our activities; the future trading of our common stock; our ability to operate as a public company; our ability to protect our proprietary information; general economic and business conditions; the volatility of our operating results and financial condition; our ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed from time to time in our filings with the SEC, or otherwise.

Information regarding market and industry statistics contained in this Report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

Business Developments

The Company was originally incorporated in the State of Delaware on March 25, 2013 under the name TYG Solutions Corp. Our original business plan was to develop iPhone and Android smartphone apps for companies who need an app for their internal and external operations. We subsequently expanded our operations to offering corporate website design services.

On July 25, 2018, the Company entered into a Share Exchange Agreement with Kannalife Sciences, Inc., a Delaware corporation (“Kannalife Sciences”), and certain stockholders of Kannalife Sciences (the “Kannalife Sciences Stockholders”). Pursuant to the terms of the Share Exchange Agreement, the Company acquired substantially all of the issued and outstanding shares of Kannalife Sciences by means of a share exchange with the Kannalife Sciences Stockholders in exchange for newly issued shares of the common stock of the Company (the “Share Exchange”). As a result of the Share Exchange, Kannalife Sciences became a 99.7% owned subsidiary of the Company. The business operations of the Company regarding iPhone and Android smartphone apps was reduced significantly to focus efforts on target therapeutics and drug discovery, and accordingly, by virtue of the Share Exchange, the Company acquired the business of Kannalife Sciences including all of its assets. The Share Exchange was accounted for as a reverse acquisition and change in reporting entity, whereby Kannalife Sciences was the accounting acquirer.

Kannalife Sciences was incorporated in the State of Delaware on August 11, 2010. Kannalife Sciences is a developmental stage phyto-medical/pharmaceutical and drug discovery company that specializes in the research, development of cannabinoid and cannabinoid-based therapeutic products derived from synthetic and botanical sources, including the Cannabis “taxa” (the word “taxa” is the plural of “taxon,” which defines a group of one or more populations of an organism or organisms to form a unit). Kannalife Sciences remains a wholly owned operational subsidiary of the Company.

On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to Kannalife, Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change to “KLFE,” and such action went effective on January 17, 2019.

On November 4, 2020, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to “Neuropathix, Inc.” The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change from “KLFE” to “NPTX.” The Company’s name and ticker symbol change was reviewed and processed by FINRA, and went effective November 6, 2020.

On August 16, 2021, the Company established and incorporated a new wholly owned subsidiary named Dermique Incorporated (“Dermique”). Dermique was established by the Company to hold, operate and commercialize all intellectual property associated with Kannalife Sciences’ previous research and development efforts to create and commercialize novel therapeutic topical over-the-counter cosmeceutical compounds to treat a variety of skin disorders, including but not limited to atopic dermatitis.

Business Overview

As a result of the Share Exchange, our core businesses are comprised of the following:

•

A drug development company focused on the research and development (“R&D”) of synthetic and phyto-medical products from:

naturally recurring sources, including but not limited to cannabis, hemp, and other similar species of plantae;

semi-synthetic sources; and

synthetic and bio-synthetic sources.

•

Drug discovery platform to evaluate and potentially treat neurological and oxidative stress related disorders such as overt hepatic encephalopathy (“OHE”), chronic traumatic encephalopathy (“CTE”) and chemotherapy induced peripheral neuropathy (“CIPN”) with high quality assured, quality controlled cGMP pharmaceutical grade semi-synthetic and synthetic cannabinoids, cannabidiol (“CBD”), and CBD-like molecules.

•

Topical skincare pre-clinical program designed to some of our patented, proprietary CBD-derived new chemical entities (“NCEs”), for use as topical solutions, ointments, and creams for disorders such as diabetic neuropathies, diabetic ulcers, and for use as an anti-pruritic. Anti-pruritics are known as anti-itch drugs and medications that inhibit the itching often associated with a variety of disorders and diseases.

Phyto cannabinoids are a class of molecules derived from cannabis plants. The two primary cannabinoids contained in Cannabis are CBD and D9-tetrahydrocannabinol (“THC”). Clinical and preclinical data suggest that CBD has positive effects on treating refractory epilepsy, FXS and arthritis, and THC has positive effects on treating pain. Interest in cannabinoid therapeutics has increased significantly over the past several years as preclinical and clinical data has emerged highlighting the potential efficacy and safety benefits of cannabinoid therapeutics. The cannabinoid therapeutics market is expected to grow significantly due to the potential benefits these products may provide over existing therapies.

We are principally involved in the research and development of NCEs such as KLS-13019; KLS-13022 (“linoneyldihydroxybenzyl ethoxycarbonyl azetidine” or “LEAÔ”); its related molecules; and synthetic CBD therapeutics through pre-clinical drug discovery and development processes. We have developed our own intellectual property portfolio and established relationships with third parties who are considered leaders in active pharmaceutical (“APIC”) contract manufacturing, formulation; and contract bulk drug manufacturing. Most of our operations have been in the pre-clinical stage of drug discovery. In 2019, we began commercialization efforts for over-the-counter cosmeceutical uses of LEAÔ, our lead compound designed to address topical skin disorders.

KLS-13019’s advanced formulation is designed to improve on some of the limitations associated with CBD, including but not limited to CBD’s low bioavailability and limited drug like properties. However, KLS-13019 has not been reviewed or approved for patient use by the FDA or any other healthcare authority in the world. Our pre-clinical studies suggest increased bioavailability, consistent plasma levels and the avoidance of first-pass liver metabolism. In addition, an in vitro study performed by us demonstrated that CBD is degraded to THC in an acidic environment such as the stomach.

In the past three years, our most recent research and development efforts have been centered on the use of KLS-13019 as a neuroprotectant and therapeutic agent to treat chronic and neuropathic pain. There is currently no FDA approved drug to treat CIPN. Our preclinical efforts in the research and development of treating CIPN with our lead compound KLS-13019 have been fostered by a successful study grant from NIH-NIDA that compared KLS-13019 to CBD in the prevention and reversal of neuropathic pain in animal models. As a result of the outcome of this and other preclinical studies, we believe there is strong evidence to support the use of KLS-13019 as a non-opioid solution to chronic and neuropathic pain in human clinical trials.

We intend to study KLS-13019 in patients with chemotherapy induced neuropathic pain, and we intend to study KLS-13023 in patients with mild traumatic brain injury. We believe that the claims made in the Pat. 9,611,213 and Pat. 10,004,722 sufficiently cover the use of the novel molecule KLS-13019 in the treatment of neuropathic pain, which is broadly defined and includes chemotherapy induced neuropathic pain (a/k/a: chemotherapy induced peripheral neuropathy).

To date, we have synthesized, pre-clinically tested and patented our proprietary CBD like NCEs, including KLS-13019, and also formulated a new CBD based molecule, KLS-13023. KLS-13023 is a target drug candidate that includes a synthetic CBD formulated in a gel capsule designed for potential use in humans, which is intended to enable more effective delivery of CBD. The formulation of this product is proprietary and currently held as a trade secret of the Company. CBD is the primary non-psychoactive component of cannabis. KLS-13023 has undergone a manufacturing feasibility study to improve some of the limitations associated with CBD, including but not limited to CBD’s low bioavailability and limited drug like properties and improvement of the delivery of CBD through the first pass in the gut and into the circulatory system. In our preclinical animal studies, KLS-13023 demonstrated effective intervention of neurodegeneration in the OHE disease state. We intend to study KLS-13023 in patients with mild traumatic brain injury. In our preclinical animal studies, KLS-13023 demonstrated effective intervention of neurodegeneration in the OHE disease state.

We believe these product candidates will provide new treatment options for patients, as well as additional treatment options for patients not currently receiving adequate relief from current treatment regimens.

We are still conducting pre-clinical studies and have not yet commenced our clinical program or tested KLS-13019 or KLS-13023 in humans. For KLS-13019, we plan to conduct Phase 1, and possibly Phase 2, clinical trials in either the United States or Australia, subject to applicable regulatory approval. We plan to conduct our Phase 1 clinical trials for KLS-13023 in either the United States or Australia, subject to applicable regulatory approval. We must file an investigational new drug application (“IND”) with the FDA and receive approval from the U.S. Drug Enforcement Agency (“DEA”) prior to commencement of any clinical trials in the United States. We expect to initiate clinical trials for KLS-13019 and KLS-13023 in the first half of 2024. We plan to submit New Drug Applications (“NDAs”) for KLS-13019 and KLS-13023 to the FDA upon completion Phase 3 clinical trials, regardless of where we conduct Phase 1 and Phase 2 clinical trials.

Pharmacokinetic and Pharmacodynamic Comparison Between KLS-13019 and CBD

Results from pharmacokinetic (“PK”) and Pharmacodynamic (“PD”) studies performed in evaluating CBD versus KLS-13019 have shown KLS-13019 to be superior in aqueous solubility (potential for drug absorption after oral administration); Log P (ratio which measures difference in solubility in two phases); bioavailability (proportion of the drug that enters the circulation); and C max at 10 mg/kg, p.o. (peak serum concentration).

Results from our pre-clinical efforts in the potential treatment of OHE and the potential treatment of CIPN have shown a marked improvement over 99.7% pure pharmaceutical grade synthetic CBD in side by side pre-clinical comparison. In a pre-clinical comparison for neuroprotection between CBD and KLS-13019, results indicated increased potency for the new molecule (KLS-13019) as determined by six assays, while both molecules exhibited efficacy in preventing oxidative stress-related toxicities back to control values.

Treatment with KLS-13019 alone, however, was 5-fold less toxic than CBD. Previous studies suggested that CBD targeted the Na+ Ca2+ (sodium-calcium) exchanger in mitochondria to regulate intracellular calcium levels, an important determinant of neuronal survival. After treatment with an inhibitor, the mNCX inhibitor (“CGP-37157”), no detectable neuroprotection from ethanol toxicity was observed for either CBD or KLS-13019. Furthermore, AM630 (a CB2 antagonist) significantly attenuated CBD-mediated neuroprotection, while having no detectable effect on KLS-13019 neuroprotection. Our studies indicated KLS-13019 was more potent and less toxic than CBD. Both molecules can act through mNCX. Based on these results, amongst other things, we believe that KLS-13019 may provide an alternative to CBD as a therapeutic candidate to treat disease associated with oxidative stress.

As previously noted, comparisons between CBD and KLS-13019 have been published in peer reviewed articles in ACS Medicinal Chemistry Letters (2016, 7, 424-428) and Journal of Molecular Neuroscience (14 August 2018).

Additional follow on studies recently published on May 10, 2019 in the Journal of Molecular Neuroscience have further advanced our studies on the mechanism of action for CBD and KLS-13019 in pre-clinical testing for the treatment of CIPN. The mechanism of action for CBD-and KLS-13019-mediated protection now has been explored with dissociated dorsal root ganglion (“DRG”) cultures using small interfering RNA (siRNA) to the mitochondrial Na+ Ca2+ exchanger-1 (“mNCX-1”). Treatment with this siRNA produced a 50–55% decrease in the immunoreactive (“IR”) area for mNCX-1 in neuronal cell bodies and a 72–80% decrease in neuritic IR area as determined with high-content image analysis. After treatment with 100 nM KLS-13019 and siRNA, DRG cultures exhibited a 75 ±5% decrease in protection from paclitaxel-induced toxicity, whereas siRNA studies with 10 μM CBD produced a 74± 3% decrease in protection. Treatment with mNCX-1 siRNA alone did not produce toxicity. The protective action of cannabidiol and KLS-13019 against paclitaxel-induced toxicity during a 5-h test period was significantly attenuated after a 4-day knockdown of mNCX-1 that was not attributable to toxicity. This data indicates that decreases in neuritic mNCX-1 corresponded closely with decreased protection after siRNA treatment. Pharmacological blockade of mNCX-1 with CGP-37157 produced complete inhibition of cannabinoid-mediated protection from paclitaxel in DRG cultures, supporting the observed siRNA effects on mechanism.

Sodium-Calcium Exchanger (“NCX”) (often denoted Na+/Ca2+ exchanger, NCX, or exchange protein) is an antiporter membrane protein that removes calcium from cells. The exchanger exists in many different cell types and animal species. The NCX is considered to be one of the most important cellular mechanisms for removing Ca2+ (calcium ions) from cells. The exchanger is usually found in the plasma membranes and the mitochondria and endoplasmic reticulum of excitable cells.

Mitochondria is a double-membrane-bound organelle found in most eukaryotic organisms. Mitochondria generate most of the cell’s supply of adenosine triphosphate (“ATP”), used as a source of chemical energy. ATP is a complex organic chemical that provides energy to drive many processes in living cells, including muscle contractions, nerve impulse propagation and chemical synthesis.

According to the October 1, 2021 journal article “Navigating Opioids and Other Strategies for Managing Cancer Pain” published in Targeted Therapies in Oncology, “The American Cancer Society estimates that more than 17 million Americans life with Cancer, and many of them hurt. Up to 60% of the patients undergoing active treatment and a third of cancer survivors report significant pain stemming either from their cancer itself or their cancer treatments. The most common treatment for significant cancer-related pain is opioid medication. A retrospective analysis of data from 169,162 people who took the National Survey on Drug Use and Health from January 2015 to December 2018 found that 54.3% of the 1,243 recent cancer survivors and 39.2% of the 3,896 less recent cancer survivors were actively using prescription opioids. There are currently no FDA approved non-opioid treatments for patients who do not respond to, or experience negative side effects with, opioid medications. We believe that KLS-13019 has the potential to address a significant unmet need in this large market by treating patients with a product that employs a differentiated non-opioid mechanism of action, and offers the prospect of pain relief without increasing opioid-related adverse side effects.

In addition to the ACS publication, our research and development efforts with KLS-13019 were also the subject of peer reviewed, preclinical studies published in April 2021 in the British Journal of Pharmacology, “Behavioral and Pharmacological Effects of Cannabidiol (CBD) and the Cannabidiol Analogue KLS-13019 in Mouse Models of Pain and Reinforcement” reported the following key results:

•

Like CBD, KLS-13019 prevented the development of mechanical sensitivity associated with paclitaxel administration.

•

In contrast to CBD, KLS-13019 was also effective at reversing established mechanical sensitivity.

•

KLS-13019 significantly attenuated acetic acid-induced stretching and produced modest effects in the hot plate assay.

•

KLS-13019 was devoid of activity at μ-, δ- or κ-opioid receptors. Lastly, KLS-13019, but not CBD, attenuated the reinforcing effects of palatable food or morphine.

The following chart indicates opioid inhibition percentages for both CBD and KLS-13019:

The study also reported the following conclusions and Implications:

KLS-13019, like CBD, prevented the development of CIPN, while KLS-13019 uniquely attenuated established CIPN. Because KLS-13019 binds to fewer biological targets, this will help to identifying molecular mechanisms shared by these two compounds and those unique to KLS-13019. Lastly, KLS-13019 may possess the ability to attenuate reinforced behavior, an effect not observed in the present study with CBD.

Clinical Timelines

As a result of the unprecedented effects of COVID-19, we have updated our clinical timelines to give effect to the significant interruption to business and financial operations worldwide as a result of the COVID-19 crisis. We will continue to monitor the progress of the shutdowns currently in effect, and revise our clinical timelines accordingly.

Product Candidate	Target Indication	Delivery Method	Current Development Status	Expected Next Steps
KLS-13019	Chemotherapy Induced	Oral Gel Capsule	Preclinical	2Q24: Initiate Phase 1
	Peripheral Neuropathy
	Mild Traumatic Brain Injury	Oral Gel Capsule	Preclinical	1Q25: Initiate Phase 1
KLS-13023	Overt Hepatic Encephalopathy	Oral Gel Capsule	Preclinical	3Q24: Initiate Phase 1
	Mild Traumatic Brain Injury	Oral Gel Capsule	Preclinical	1Q25: Initiate Phase 1

With respect to certain other proprietary compounds underlying Pat. 9,611,213, we plan on pursuing topical solutions as potential relief creams and/or ointments for neuropathic pain, anti-inflammation, anti-pruritic and skin ulcers. We are considering commercialization routes that include, but are not limited to, filing an FDA Monograph and have already pursued and completed a commercialization path to the marketplace having received INCI certification and registration with the PCPC for LEAÔ.

In preclinical testing, certain molecules under Pat. 9,611,213 were screened for neuroprotection and may have the potential mechanism of action for reducing inflammation and neuropathic pain. These molecules indicate that they are more soluble than CBD, also deemed a neuroprotectant with potential anti-inflammatory properties. A molecule that is potentially more water soluble than CBD in this regard may be good candidate(s) for use in topical applications.

We believe that we will be able to raise sufficient capital to proceed forth with a Phase 1a human safety trial for the treatment of Chemotherapy Induced Peripheral Neuropathy. All preclinical work in this indication, including animal toxicity studies, are expected to be completed before the end of the third quarter 2023. We plan on entering into clinical trials sometime in the second quarter 2024.

Additionally, we believe that we will be able to raise sufficient capital to proceed forth with a Phase 1a human safety trial for the treatment of OHE. All preclinical work in this indication, including animal toxicity studies, are expected to be completed before the end of the first quarter 2024. We plan on entering into clinical trials sometime in the third quarter 2024.

We intend to seek additional capital to proceed with our business plan regarding additional drug pipeline opportunities.

NIH-NINDS Phase 2 STTR Study Grant Award

On September 28, 2021, we received a notice of award for a $2.97 million Phase 2 STTR Study Grant (the “NINDS Study Grant Award”) from National Institutes of Health (“NIH”) – National Institute of Neurological Disorders and Stroke (“NINDS”). The NINDS Study Grant Award is funded through the NIH HEAL Initiative (“Helping End Addiction Long-Term”) for Development of Therapies and Technologies Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. The NINDS Study Grant Award sets forth the funding allocation of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3. Of significant collateral importance is the current epidemic of opioid addiction and abuse by patients in the United States and around the globe. Adding to the equation is the off-label use of opioids and gabapentinoids for chronic and neuropathic pain as a result of the unmet medical need and no FDA approved non-opioid drug to treat chronic and neuropathic pain, specifically chemotherapy-induced peripheral neuropathy (“CIPN”).

Components of Results of Operations

Our net losses were $1,595,605 and $ 1,328,574 for the three months ended March 31, 2022 and 2021, respectively. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

Financial Operations Overview

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

Revenues

Our revenues consist of state and federal research grants and fees received from research services for third-party product development. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met.

Research and Development Expenses

Our research and development expenses consist of expenses incurred in development and preclinical studies relating to our product candidates, including:

•

expenses associated with preclinical development;

•

personnel-related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation;

•

payments to third-party contract research organizations (“CROs”) contractor laboratories and independent contractors; and

•

depreciation, maintenance and other facility-related expenses.

We expense all research and development costs as incurred. Preclinical development expenses for our product candidates are a significant component of our current research and development expenses. Product candidates in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We track and record information regarding external research and development expenses for each grant, study or trial that we conduct. From time to time, we intend to use third-party CROs, and have used contractor laboratories and independent contractors in preclinical studies. We recognize the expenses associated with third parties performing these services for us in our preclinical studies based on the percentage of each study completed at the end of each reporting period.

We incurred research and development expenses of $219,760 and $128,648 for the three months ended March 31, 2022 and 2021, respectively.

We expect that our research and development expenses in 2022 and for the next several years will be higher than in 2021 as a result of the work needed for our expected initiation of our Phase 1 clinical trials of KLS-13019 and KLS-13023. These expenditures are subject to numerous uncertainties regarding timing and cost to completion. Completion of our preclinical development and clinical trials may take several years or more and the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:

•

the number of sites included in the clinical trials;

•

the length of time required to enroll suitable patients;

•

the size of patient populations participating in the clinical trials;

•

the duration of patient follow-ups;

•

the development stage of the product candidates; and

•

the efficacy and safety profile of the product candidates.

Due to the early stages of our research and development, we are unable to determine the duration or completion costs of our development of KLS-13019 and KLS-13023. As a result of the difficulties of forecasting research and development costs of KLS-13019 and KLS-13023 as well as the other uncertainties discussed above, we are unable to determine when and to what extent we will generate revenues from the commercialization and sale of an approved product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our executive, finance, accounting, legal and human resource functions. Our general and administrative expenses also include facility and related costs not included in research and development expenses, professional fees for legal services, including patent-related expenses, consulting, tax and accounting services, insurance and general corporate expenses. We expect that our general and administrative expenses will increase with the continued development and potential commercialization of our product candidates.

We expect that our general and administrative expenses in 2022 and for the next several years will be higher than in 2021 as we increase our headcount. We also anticipate increased expenses relating to our operations as a public company, including increased costs for the hiring of additional personnel, and for payment to outside consultants, including lawyers and accountants, to comply with additional regulations, corporate governance, internal control and similar requirements applicable to public companies, as well as increased costs for insurance.

Interest Income (Expense), net

Interest income consists primarily of interest earned on our money market bank account. Interest expense consists of interest expense on our notes payable.

Income Taxes

We file income tax returns in the United States federal jurisdiction and in various state and local jurisdictions. In the normal course of business, we are subject to examination by taxing authorities. The tax years ending 2018 through 2021 remain subject to examination for federal tax purposes and remain subject to examination in significant state tax jurisdictions.

As of December 31, 2021, we had approximately $8.8 million of federal operating loss carryforwards. These operating loss carryforwards will begin to expire in 2033. The Tax Reform Act of 1986, or the Act, provides for limitation on the use of net operating loss and research and development tax credit carryforwards following certain ownership changes (as defined by the Act) that could limit our ability to utilize these carryforwards. We may have experienced various ownership changes, as defined by the Act, as a result of past financings. Accordingly, our ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes; therefore, we may not be able to take full advantage of these carryforwards for federal income tax purposes.

The closing of the Share Exchange transaction, together with private placements and other transactions that have occurred since our inception, may trigger, or may have already triggered, an “ownership change” pursuant to Section 382 of the Internal Revenue Code of 1986. If an ownership change is triggered, it will limit our ability to use some of our net operating loss carryforwards. In addition, since we will need to raise substantial additional funding to finance our operations, we may undergo further ownership changes in the future, which could further limit our ability to use net operating loss carryforwards. As a result, if we generate taxable income, our ability to use some of our net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could result in increased future tax liability to us.

Critical Accounting Policies and Use of Estimates

We have based our management’s discussion and analysis of financial condition and results of operations on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to preclinical development expenses, stock-based compensation, convertible debt and derivative liabilities. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully discussed in Note 2 to our condensed consolidated financial statements appearing above, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.

Research and Development Expenses

We rely on third parties to conduct our preclinical studies and to provide services, including data management, statistical analysis and electronic compilation. Once our clinical trials begin, at the end of each reporting period, we will compare the payments made to each service provider to the estimated progress towards completion of the related project. Factors that we will consider in preparing these estimates include the number of patients enrolled in studies, milestones achieved and other criteria related to the efforts of our vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, we will record net prepaid or accrued expenses related to these costs.

Fair Value of Common Stock and Stock-Based Compensation

We account for grants of stock options and restricted stock to employees based on their grant date fair value, and recognize compensation expense over the vesting periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes option pricing model, and we estimate the fair value of restricted stock based on the fair value of the underlying common stock as determined by our board of directors or the value of the services provided, whichever is more readily determinable. We account for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms.

In the absence of a public trading market for our common stock, on each grant date, we develop an estimate of the fair value of our common stock for the option and restricted stock grants based in part on input from an independent third-party valuation firm. We determined the fair value of our common stock using methodologies, approaches and assumptions consistent with the AICPA Practice Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation. In addition, our board of directors considered various objective and subjective factors, along with input from management and an independent third-party valuation firm, to estimate the fair value of our common stock, including external market conditions affecting the pharmaceutical industry, trends within the pharmaceutical industry, the prices at which we sold shares of our different series of preferred stock, the superior rights and preferences of each series of preferred stock relative to our common stock at the time of each grant, our results of operations and financial position, the status of our research and development efforts and progress of our preclinical programs, our stage of development and business strategy, the lack of an active public market for our common and our preferred stock, and the likelihood of achieving a liquidity event.

Derivative liabilities

FASB ASC 815, Derivatives and Hedging, requires all derivatives to be recorded on the consolidated balance sheet at fair value. As a result, certain derivative warrant liabilities (namely those with a price protection feature) are separately valued and accounted for on our balance sheet, with any changes in fair value recorded in earnings. On our consolidated balance sheets as of March 31, 2022 and December 31, 2021, we engaged a specialist who used the Monte Carlo model to estimate the fair value of these warrants. Key assumptions of the Monte Carlo model include the market price of our stock, the exercise price of the warrants, applicable volatility rates, risk-free interest rates, expected dividends and the instrument’s remaining term. These assumptions require significant management judgment. In addition, changes in any of these variables during a period can result in material changes in the fair value (and resultant gains or losses) of this derivative instrument.

Equity Purchase Agreement with Cross & Company

Results of Operations – For the Three Month Periods Ended March 31, 2022 and 2021

Revenues

Revenues for the three months ended March 31, 2022, was $207,980 compared to $32,000 for the three months ended March 31, 2021. The increase in revenue was the result of the NIH grant received in September 2021.

Research and Development Expenses

Research and development expenses increased by $91,112, or 71%, to $219,760 for the three months ended March 31, 2022, from $128,648 for the three months ended March 31, 2021. The increase in spending was primarily made possible by the NIH grant received in September 2021.

General and Administrative Expenses

General and administrative expenses decreased by $632,609, or 64%, to $354,580 for the three months ended March 31, 2022, from $987,189 for the three months ended March 31, 2021. This decrease was primarily due to a decrease in compensation to consultants and stock based compensation.

Liquidity and Capital Resources

Since our inception, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of preferred stock and convertible promissory notes, state and federal grants and research services. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of March 31, 2022, our principal source of liquidity was through financing activities, which included proceeds from the issuance of convertible debt of $150,000, sale and issuance of equity securities, and the receipt of grants. Our working capital deficit was $3,489,930 as of March 31, 2022.

As discussed elsewhere in this Report, on September 18, 2020, the Company entered into an Equity Purchase Agreement with Cross and Company, pursuant to which we have the right to “put,” or sell, up to 8,108,108 shares of our common stock to Cross. Unless terminated earlier, Cross’s purchase commitment will automatically terminate on the earlier of the date on which Cross shall have purchased shares pursuant to the Equity Purchase Agreement for an aggregate purchase price of $6,000,000 or September 18, 2023. The purchase price per share is calculated at a fifteen percent discount of the lowest trading price of the Company’s common stock during the ten days after Cross and Co. receives the shares. As of March 31, 2022, we had sold an aggregate of 2,000,000 shares under the Equity Purchase Agreement for total gross proceeds to the Company of $53,610.

On September 28, 2021, we received a notice of award for the $2.97 NINDS Study Grant Award from the NIH –NINDS. The NINDS Study Grant Award sets forth the funding allocation of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3. During the three months ended March 31, 2022, the Company recognized $207,980 in grant revenue in connection with this grant.

On March 21, 2022, we issued three convertible promissory notes to certain investors, which promissory notes have an aggregate face value of $150,000. Each of the promissory notes is (i) unsecured; (ii) bears interest at a rate of 3% per annum; (iii) matures on March 21, 2032; and (iv) in the sole discretion of the holder, is convertible, in whole or in part, into restricted shares of our common stock at a conversion price equal to the lesser of $0.01 or 70% of the average of the two lowest closing prices of our common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.9% of our issued and outstanding common stock as of the date of the conversion.

Our sources of liquidity and cash flows are used to fund ongoing operations and research and development projects for our product candidates. In addition, as part of our business strategy, we occasionally evaluate potential acquisitions of businesses, products and technologies, and minority equity investments. Accordingly, a portion of our available cash may be used at any time for the acquisition of complementary products or businesses or minority equity investments. Such potential transactions may require substantial capital resources, which may require us to seek additional debt or equity financing. We cannot assure you that we will be able to successfully identify suitable acquisition or investment candidates, complete acquisitions or investments, integrate acquired businesses into our current operations, or expand into new markets. Furthermore, we cannot provide assurances that additional financing will be available to us in any required time frame and on commercially reasonable terms, if at all.

Equity Financings

For the three months ended March 31, 2022, we received net proceeds of $53,610 for the sale of common stock. For the three months ended March 31, 2021, we received net proceeds of $757,320 for the sale of common stock.

Debt Financings

For the three months ended March 31, 2022, we received net proceeds of $150,000 from the sale of convertible notes.

Future Capital Requirements

We have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. As discussed in further detail below, we expect that our expenses will continue to grow and, as a result, we will need to generate significant product revenues to achieve profitability. We may never achieve profitability. As such, we are dependent on obtaining, and are continuing to pursue, the necessary funding from outside sources, including obtaining additional funding from the sale of securities in order to continue our operations. Without adequate funding, we may not be able to meet our obligations. We believe these conditions raise substantial doubt about our ability to continue as a going concern.

We are currently raising capital and we anticipate raising funds sufficient to commence a Phase 1a and 1b clinical trials for KLS-13019 for patients with chemotherapy induced peripheral neuropathy. We anticipate, based on current estimates, that costs associated Phase 1a and 1b clinical trials for KLS-13019 will be approximately $2.30 million.

Management of the Company believes that it will need to seek additional sources of capital to facilitate and carry out its business plan of proceeding forth with commencing a Phase 2a clinical trial for KLS-13019 for patients with chemotherapy induced peripheral neuropathy; commencing a Phase 1a clinical trial for KLS-13019 for patients suffering from the effects of mild traumatic brain injury; and commencing a Phase 1a clinical trial for KLS-13023 for patients suffering with overt hepatic encephalopathy. The cost of commencing and conducting these trials will likely be in the tens of millions of dollars.

Furthermore, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.

Our expectations regarding future cash requirements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we make in the future. We have no current understandings, agreements or commitments for any material acquisitions or licenses of any products, businesses or technologies. We may need to raise substantial additional capital in order to engage in any of these types of transactions.

We expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for either of our product candidates, we will incur significant sales, marketing and outsourced manufacturing expenses. In addition, we expect to incur additional expenses to add operational, financial and information systems and personnel, including personnel to support our planned product commercialization efforts. We also expect to incur significant costs to comply with corporate governance, internal controls and similar requirements applicable to us as a public company.

Our future use of operating cash and capital requirements will depend on many forward-looking factors, including, without limitation, the following:

•

the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates;

•

the clinical development plans we establish for these product candidates;

•

the number and characteristics of product candidates that we develop or may in-license;

•

the terms of any collaboration agreements we may choose to execute;

•

the outcome, timing and cost of meeting regulatory requirements established by the DEA, the FDA, the EMA or other comparable foreign regulatory authorities;

•

the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

•

the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;

•

costs and timing of the implementation of commercial scale manufacturing activities; and

•

the cost of establishing, or outsourcing, sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.

To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities for the three months ended March 31, 2022, and 2021:

	Three Months Ended March 31,
	2022			2021
Statement of Cash Flows Data:
Total net cash provided by (used in):
Operating activities	$	(113,676	)	$	(445,879	)
Investing activities		—			(8,100	)
Financing activities		200,193			755,295
Increase in cash	$	86,517		$	301,316

Operating Activities

Net cash used in operating activities was $113,676 for the three months ended March 31, 2022, including $21,905, net, used in working capital. The noncash expenses were primarily related to the stock based compensation of $277,154, noncash interest expense of 263,673 and change in fair value of derivative liabilities $924,692.

Net cash used in operating activities for the three months ended March 31, 2021 was $445,879, including $826,092 of net non-cash expenses and a $56,603 net change in operating assets and liabilities. The net noncash expenses were predominantly related to the stock based compensation and issuance of common stock shares of $611,244, amortization of debt discount of $100,187 and change in fair value of derivative liabilities of $110,216. The change in operating assets and liabilities was due to a $114,302 decrease in accounts payable and accrued expenses, a $74,748 increase in payroll and related liabilities, a $123,000 increase in prepaid expenses and a $26,843 decrease in due to related party and prepaid expenses.

Investing Activities

Net cash used in investing activities for the three months ended March 31, 2022 was $0 compared to $8,100 for the same period in the prior fiscal year. This decrease was due to the purchase of equipment in 2021.

Financing Activities

For the three months ended March 31, 2022, cash provided by financing activities was $200,193 compared to $755,295 for the three months ended March 31, 2021. This decrease was due to a significant increase of proceeds from the sale of common stock in 2021, partially offset by a decrease in proceeds from convertible notes payable and proceeds from loans payable.

Inflation

We have not been affected materially by inflation during the periods presented, and no material effect is expected in the near future.

Known Trends or Uncertainties

We have seen some consolidation in our industry during economic downturns. These consolidations have not had a negative effect on us to date; however, should consolidations and downsizing in the industry continue to occur, those events could adversely impact our future revenues and earnings, if any.

As discussed in this Report, the world has been affected due to the COVID-19 pandemic. Until the pandemic has passed, there remains uncertainty as to the effect of COVID-19 on our business in both the short and long-term.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, except for operating leases, or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Under the supervision and with the participation of management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal controls over financial reporting based on the framework in “Internal Control Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this evaluation, management has concluded that our internal control over financial reporting was ineffective as of March 31, 2022, to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Our reporting was ineffective due to a lack of sufficient resources to hire a support staff in order to separate duties between different individuals. The Company lacks the appropriate personnel to handle all the varying recording and reporting tasks on a timely basis. Steps that the Company believes it must undertake is to retain a consulting firm to, among other things, design and implement adequate systems of accounting and financial statement disclosure controls during the current fiscal year to comply with the requirements of the SEC. We believe that the ultimate success of our plan to improve our disclosure controls and procedures will require a combination of additional financial resources, outside consulting services, legal advice, additional personnel, further reallocation of responsibility among various persons, and substantial additional training of those of our officers, personnel and others, including certain of our directors such as our committee chairs, who are charged with implementing and/or carrying out our plan.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as required in Rule 13a-15(b). We are conducting an evaluation to design and implement adequate systems of accounting and financial statement disclosure controls. We expect to complete this review during 2022 to comply with the requirement of the SEC. We believe that the ultimate success of our plan to improve our internal control over financial reporting will require a combination of additional financial resources, outside consulting services, legal advice, additional personnel, further reallocation of responsibility among various persons, and substantial additional training of our officers, personnel and others, including certain of our directors such as our Chairman of the Board and Chief Financial Officer, who are charged with implementing and/or carrying out our plan. It should also be noted that the design of any system of controls and procedures is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls or our internal control over financial reporting, or any system we design or implement in the future, will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control

There have not been any changes in our internal control over financial reporting during the three month period ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

There are no pending legal proceeding relating to our company and its CEO to which we are a party, and to our knowledge there are no material proceedings to which any of our directors, executive officers or affiliates is a party adverse to us or which have a material interest adverse to us.

Item 1A. Risk Factors.

Please carefully consider the information set forth in this Report and the risk factors discussed in Part I, Item I A. of our Annual Report on Form 10-K for the year ended December 31, 2021, which could materially affect our business, financial condition or future results. In evaluating our business, you should carefully consider the risk factors discussed in our Annual Report on Form 10-K, as updated by our subsequent filings under the Exchange Act. The occurrence of any of the risks discussed in such filings, or other events that we do not currently anticipate or that we currently deem immaterial, could harm our business, prospects, financial condition and results of operations. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, although we may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number	Description
10.1	Form of Convertible Note dated March 21, 2022.
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 *	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101. INS	XBRL Instance Document
101. SCH	XBRL Taxonomy Extension Schema Document
101. CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101. DEF	XBRL Taxonomy Extension Definition Linkbase Document
101. LAB	XBRL Taxonomy Extension Label Linkbase Document
101. PRE	XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

*	Filed herewith.

These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NEUROPATHIX, INC.

Date: May 23, 2022	By:	/s/ Dean Petkanas
		Dean Petkanas
		Chief Executive Officer and Chairman (Principal Executive Officer)

Date: May 23, 2022	By:	/s/ Mark Corrao
		Mark Corrao
		Chief Financial Officer (Principal Financial and Accounting Officer)

NEUROPATHIX, INC. 10-Q